Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes (based on the World Health Organization \[WHO\] diagnostic criteria) for at least 1 year.~* Have diet and exercise therapy only (no oral antihyperglycemic medication for at least 3 months prior to screening).~* Have a fasting blood glucose value of ≥120 and ≤200 milligrams per deciliter (mg/dL) at screening.~* Have a screening body weight of ≥50 and ≤80 kilograms.~Exclusion Criteria:~* Have known allergies to dulaglutide, or other glucagon-like peptide-1 (GLP-1) receptor agonists.~* Have had a clinically significant cardiovascular disease.~* Have a known clinically significant gastric emptying abnormality or have undergone gastric bypass surgery or restrictive bariatric surgery.~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease.~* Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis.~* Have an estimated glomerular filtration rate (eGFR) \<30 milliliters/minute/1.73 meter squared.~* In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dulaglutide, Placebo (Type: EXPERIMENTAL): Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
- Placebo, Dulaglutide (Type: EXPERIMENTAL): Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).